

IL-29, Human CellExp™, human recombinant

CATALOG #:	6473-10	10 µg
	6473-50	50 µg
ALTERNATE NAMES:	Interleukin-29, IL-29, IFN-Lambda 1, Interferon-Lambda 1, Cytokine ZCYTO21, IL29, IFNL1, ZCYTO21.	
SOURCE:	Human 293 Cell Expressed	
PURITY:	> 95% by SDS - PAGE	
MOL. WEIGHT:	29 and 35 kDa, monomer, glycosylated	
ENDOTOXIN LEVEL:	< 1.0 EU per 1 µg of protein	
FORMULATION:	Lyophilized in PBS.	
RECONSTITUTION:	Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.	
STORAGE CONDITIONS:	Aliquot and store at -20°C or -70°C. Avoid repeated freezing and thawing cycles.	

ADVANTAGES:


- Animal-derived product free
- High Activity
- Authentic Glycosylation

DESCRIPTION:

IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor β (IL10RB) and interleukin 28 receptor α . IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumor activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-Lambda 1 antiviral and antiproliferative activity requires Interferon-Lambda 2 receptor tyrosine residues.

BIOLOGICAL ACTIVITY:

ED₅₀ is typically 0.5 to 5 ng/mL. The specific activity was determined by the dose-dependent protection of the cytopathic effect on A549 cells (human lung adenocarcinoma epithelial cell line) that were challenged with encephalomyocarditis (EMC) virus.



Human Cell^{exp} Human Recombinant IL-29

RELATED PRODUCTS:

- IL-29, human recombinant (Cat # 4981-20, -1000)

FOR RESEARCH USE ONLY! Not to be used in humans.